PMID: 2123971Oct 1, 1990Paper

Behavioural effects of serotonin agonists and antagonists in the rat and marmoset

Neuropharmacology
P J ElliottA G Hayes

Abstract

The present study was conducted to investigate the effects of various 5-hydroxytryptamine (5-HT) agonists and antagonists on motor behaviour in rats and marmosets. Various motor-based responses were assessed after central or peripheral administration of 5-HT agents to rats and marmosets. Drugs acting as agonists at the 5-HT1A receptor (8-OHDPAT, gepirone, BMY-7378, NAN-190, PAPP (LY165163) and flesinoxan) and 5-HT2/1C receptors (DOI) were found to reverse neuroleptic-induced catalepsy in the rat whereas 5-HT2/1C antagonists (mianserin, ritanserin and ICI-170,809) and the 5-HT1 antagonist ((+/-)pindolol) increased catalepsy. Agonists acting at 5-HT3 receptors (phenylbiguanide and 2-methyl-5-HT) had no effect on catalepsy. The putative 5-HT1A antagonist, (+/-) pindolol, attenuated the reversal of catalepsy by 8-OHDPAT. Although both 8-OHDPAT and BMY-7378 were tested, only the latter was found to reduce apomorphine-induced stereotypy. Bilateral or unilateral infusions of 8-OHDPAT, BMY-7378 or pindolol into the substantia nigra of non-lesioned rats had no effect on spontaneous locomotor or rotational activity, respectively. However, 8-OHDPAT and BMY-7378 were found to increase or decrease motor activity, after injection into the me...Continue Reading

Citations

Jan 1, 1993·Psychopharmacology·K A YoungP B Hicks
Dec 12, 1994·European Journal of Pharmacology·P ProtaisE Mocaër
May 12, 1994·European Journal of Pharmacology·C A Seyfried, G D Bartoszyk
Feb 21, 1994·European Journal of Pharmacology·P SalmiS Ahlenius
Dec 27, 1995·European Journal of Pharmacology·M L Wadenberg, S Ahlenius
Jan 1, 1995·Life Sciences·C J SchmidtM G Palfreyman
Jan 1, 1996·Neuroscience and Biobehavioral Reviews·M L Wadenberg
May 1, 1996·Neuroscience·K Eberle-WangM F Chesselet
May 7, 1998·European Journal of Pharmacology·H O KalkmanM D Tricklebank
Sep 28, 1999·European Journal of Pharmacology·L P Nucci-da-SilvaE A Del Bel
Jan 1, 1997·Life Sciences·C M Queiroz, R Frussa-Filho
Sep 5, 2003·Physiology & Behavior·Eberhard Fuchs, Gabriele Flügge
Jul 19, 2000·Pharmacology, Biochemistry, and Behavior·C Wilson, M Pulido
Jan 4, 1998·Pharmacology, Biochemistry, and Behavior·J L Roffman, L A Raskin
Nov 14, 1997·Neuroscience and Biobehavioral Reviews·S A JosselynR J Beninger
Dec 14, 1999·Behavioural Brain Research·W Hauber, S Lutz
Oct 6, 1999·Progress in Neuro-psychopharmacology & Biological Psychiatry·U RaoR E Poland
Feb 24, 2007·Progress in Neurobiology·Christian P MüllerMaria A De Souza Silva
Oct 13, 2015·Progress in Neurobiology·Yukihiro OhnoMasashi Sasa
Feb 17, 2010·Neuroscience and Biobehavioral Reviews·Marieke LangenSarah Durston
Jul 3, 2021·Brain Sciences·Roberto KellerMarco O Bertelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here